Squawk Pod

Priscilla Chan on CZI's AI-driven mission to cure all disease via BioHub and rare disease models

43 min Listen to the original Episode page
BiotechnologyArtificial IntelligenceRare DiseasesGene TherapyHealthcare InnovationPhilanthropy

Summary

Priscilla Chan discusses the Chan Zuckerberg Initiative's (CZI) mission to cure, prevent, and manage all disease, accelerated by AI integration through BioHub. She highlights how rare disease patient groups serve as trailblazers for faster, collaborative biomedical research. Chan explains that AI models like ESM enable rapid protein structure computation and design, shifting medicine from trial-and-error to systematic discovery. She contrasts this with traditional pharmaceutical timelines, citing rare disease therapies developed in under a decade as evidence of this accelerated pace.

Key takeaways

  1. 1
    CZI's early investment in single-cell sequencing helped identify new cell types, such as a lung cell subtype uniquely affected by COVID-19.

    Priscilla Chan · 17:13

  2. 2
    We funded maybe a third now of what is now the human cell atlas looking at the RNA transcriptome. But because we put it out there as open science, open source, come join us. People started using it and then also realizing, oh, this is useful.

    Priscilla Chan · 18:48

  3. 3
    Chan notes that some rare disease groups have gone from identifying a mutation to designing a gene therapy in humans within 10 years.

    Priscilla Chan · 29:47

Episode sections

  1. 0:00 – 2:41

    Introduction and CZI Mission

    Becky Quick introduces the podcast and guest Priscilla Chan, who states the Chan Zuckerberg Initiative's (CZI) mission to cure, prevent, and manage all disease. Quick shares her personal motivation, having a daughter with the rare genetic disease SYNGAP 1.

  2. 2:41 – 4:05

    BioHub and AI Integration

    Chan explains the launch of BioHub in 2025, a nonprofit combining frontier AI and biology. The initiative aims to use AI, massive compute, and human cell datasets to create virtual cells and immune systems to accelerate scientific discovery.

  3. 4:05 – 13:36

    Chan's Personal Motivation and Medical Background

    Chan discusses her background as a pediatrician and her drive to understand the 'why' behind diseases, stemming from her grandfather's death from cancer. She describes her training at UCSF and the realization that medical textbooks lack knowledge on rare diseases.

  4. 13:36 – 19:28

    CZI Origins and Single-Cell Sequencing

    Chan recounts founding CZI with Mark Zuckerberg in 2015 while expecting their first child. She details early investments in single-cell sequencing, which helped build the Human Cell Atlas and revealed new cell types, laying the groundwork for understanding disease at a molecular level.

  5. 19:28 – 23:36

    AI, LLMs, and Protein Folding

    Chan explains the integration of Large Language Models (LLMs) and Evolutionary Scale Models (ESM) into their research. She highlights that ESM can compute structures for 1.1 billion proteins in a week, enabling the design of proteins to correct genetic errors.

  6. 23:36 – 26:58

    The Rare Disease Model as a Gateway

    Chan argues that the rare disease community's approach to personalized medicine serves as a blueprint for treating all diseases. She contrasts this with current practices for common diseases like depression, where treatment is often trial-and-error.

  7. 26:58 – 30:28

    Timeline and Future Outlook

    Chan revisits the CZI mission to cure all disease, noting that AI has accelerated the timeline from 'by the end of the century' to potentially much sooner. She cites rare disease groups developing gene therapies in humans within 10 years as evidence of this speed.

  8. 30:28 – 31:31

    BioHub and Rare Rarest One

    Chan distinguishes BioHub's focus on basic science and AI from the broader CZI. She briefly introduces the 'Rare Rarest One' program, which started eight years ago to address the most severe rare diseases.

  9. 31:31 – 33:54

    Rare Disease Groups as Pioneers

    Priscilla Chan explains that rare disease patient groups are accelerating biomedical research through natural history registries and clinical trials, achieving FDA-approved genetic therapies in a fraction of the time typically seen. She views these groups as trailblazers setting the standard for the future of all medicine.

  10. 33:54 – 35:58

    Applying Lessons to General Medicine

    Chan discusses how the collaborative models and patient power developed by rare disease groups can be applied to understand the human body more broadly, potentially accelerating treatments for all diseases rather than just rare ones.

  11. 35:58 – 37:03

    The Chan Zuckerberg Initiative's Approach to Learning

    Chan describes her and Mark Zuckerberg's strategy of setting a broad goal to cure, prevent, and manage all disease, then iterating quickly. She contrasts Zuckerberg's engineering perspective of building foundational learning engines with her medical focus on patient impact.

  12. 37:03 – 41:02

    Biohub and Personal Motivation

    Chan highlights the role of Biohub as a learning engine for building biomedical foundations. She shares personal motivations rooted in her time as a pediatrician at UCSF, citing specific patients with cystic fibrosis and pediatric cancer who influenced her perspective on medical outliers and treatment failures.

  13. 41:02 – 42:45

    Neuroplasticity and Hope for Neurodevelopmental Disorders

    A guest speaker discusses neuroplasticity in children with neurodevelopmental disorders, comparing the ability to learn a new language as an adult to a child's potential to learn skills like speech or independence despite their condition.

Assets discussed

AssetKindStanceContext
Meta PlatformsMETAequityneutralYou said that you were going to give ninety-nine 99% percent of of your wealth from from Meta in your lifetime that you'd be giving that away.

“Stance” is how the speakers talked about the asset, not a recommendation.

Claims worth verifying

CZI was co-founded by Priscilla Chan and Mark Zuckerberg with the mission to cure, prevent, and manage all disease.

Unidentified speaker (UNKNOWN) ·0:32

How to verify: CZI official website (chanzuckerberg.com) or CZI annual reports filed with the IRS (Form 990). For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

BioHub was launched in 2025 as a nonprofit committing billions of dollars to curing and preventing all disease.

Unidentified speaker (speaker_1) ·2:41

How to verify: BioHub official website or press releases from CZI/BioHub dated 2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

BioHub is the first research organization combining frontier AI and frontier biology.

Unidentified speaker (speaker_3) ·3:02

How to verify: BioHub mission statement or press releases describing BioHub's unique structure. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

CZI's early investment in single-cell sequencing helped discover a new type of lung cell affected by COVID-19.

Priscilla Chan ·17:09

How to verify: Scientific publications citing CZI funding regarding SARS-CoV-2 lung cell research (e.g., Nature, Cell journals) from 2026-2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

CZI funded approximately one-third of the Human Cell Atlas.

Priscilla Chan ·18:48

How to verify: Human Cell Atlas publications or CZI grant databases showing funding contributions to the HCA project. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

ESM models can compute structures for 1.1 billion proteins in a week.

Unidentified speaker (speaker_3) ·20:55

How to verify: Publications from the ESM team (e.g., Nature journal) detailing protein structure prediction capabilities and scale. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Primary source

GLP-1 drugs originated from research on Gila Monster venom.

Unidentified speaker (speaker_3) ·21:54

How to verify: Historical medical literature or pharmaceutical company histories regarding the discovery of exenatide or similar GLP-1 agonists. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Primary source

Mark Zuckerberg dropped out of college; Priscilla Chan finished many more degrees.

Priscilla Chan ·9:39

How to verify: Public biographies of Mark Zuckerberg and Priscilla Chan (e.g., Wikipedia, official bios). For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

CZI contributors gave 99% of their wealth from Meta in their lifetime.

Unidentified speaker (UNKNOWN) ·15:48

How to verify: The Giving Pledge website or CZI financial disclosures. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Some rare disease groups have gone from identifying a mutation to designing a gene therapy in humans within 10 years.

Priscilla Chan ·29:47

How to verify: Clinical trial registries (ClinicalTrials.gov) or FDA approvals for gene therapies targeting rare diseases launched around 2026-2026. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Rare disease groups are driving research and clinical trials that didn't exist before, leading to FDA-approved genetic therapies in 8-10 years.

Priscilla Chan ·32:57

How to verify: Review FDA approval dates for orphan drug genetic therapies (e.g., Zolgensma, Luxturna) and compare against the timeline of patient registry formation and research initiation reported by organizations like NORD or specific disease foundations. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Priscilla Chan worked as a pediatrician at UCSF.

Unidentified speaker (speaker_3) ·38:28

How to verify: Check Priscilla Chan's biography on the Chan Zuckerberg Initiative website or UCSF medical school alumni records. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

The Chan Zuckerberg Initiative and Biohub were co-founded by Priscilla Chan and Mark Zuckerberg.

Unidentified speaker (speaker_3) ·35:35

How to verify: Review the 'About' section of the Chan Zuckerberg Initiative website or Biohub's official site for founding information. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Mark Zuckerberg is the founder of Meta.

Unidentified speaker (speaker_3) ·35:58

How to verify: Check Meta Platforms Inc. (META) corporate history or SEC filings (e.g., 10-K) for founding details. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Primary source

Chan cites a specific cystic fibrosis patient who was a 'picture of health' and a pediatric cancer patient who relapsed after eight weeks of daily hospital care as key influences.

Unidentified speaker (speaker_3) ·38:40

How to verify: This is a personal anecdote; verification is limited to published interviews or biographies where Chan recounts these specific stories. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Chan states that rare disease groups are achieving results in 'lightning speed' compared to traditional medicine.

Priscilla Chan ·33:17

How to verify: Compare average drug development timelines (typically 10-15 years) reported by the FDA or Tufts Center for Drug Development against the accelerated timelines reported for rare disease gene therapies. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

The goal of the Chan Zuckerberg Initiative is to 'cure, prevent, and manage all disease.'

Priscilla Chan ·36:09

How to verify: Review the mission statement on the Chan Zuckerberg Initiative website. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Biohub is described as a 'learning engine' being built to advance biomedical research.

Priscilla Chan ·37:03

How to verify: Review Biohub's mission statements or research publications detailing their infrastructure and collaborative models. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Chan mentions that rare disease groups are building 'natural history registries' and 'patient samples' to accelerate research.

Priscilla Chan ·31:39

How to verify: Search for public rare disease registries (e.g., in the NIH Genetic and Rare Diseases Information Center) that list CZI or Biohub as funding partners. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Chan references 'foundational bottlenecks' (likely foundations) being built today to speed up research-to-trial transitions.

Unidentified speaker (speaker_3) ·35:35

How to verify: Review CZI or Biohub strategic reports on infrastructure investments in biotech research. For recent events, verify 2026-08-20 through 2026-11-20. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify BioHub's nonprofit status and funding sources via IRS Form 990 filings.
  • Review the Human Cell Atlas publication and CZI's specific contribution percentage in peer-reviewed journals.
  • Check clinical trial databases (e.g., ClinicalTrials.gov) for rare disease gene therapies developed within the 10-year window cited.
  • Analyze ESM model performance metrics and protein structure prediction accuracy against established databases like PDB.
  • Assess the regulatory timeline for FDA approval of recent rare disease gene therapies to validate the '10-year' claim.
  • Investigate CZI's financial disclosures for conflicts of interest regarding investments in AI or biotech companies.
  • Compare traditional pharmaceutical R&D timelines (10-15 years) with the cited rare disease timelines using industry reports.
  • Look for counter-arguments regarding the scalability of rare disease models to common, complex diseases like depression or diabetes.
Full transcriptexpand

0:00Unidentified speaker (speaker_0): AI is here, transforming how we work, live, and lead. And the women I talk to aren't waiting for the future, they're shaping it. I'm Julia Borston, Senior Media and Tech Correspondent at CNBC. This is CNBC Changemakers, where I talk with the female leaders transforming business as AI reshapes the world. Follow and listen to CNBC Changemakers, women leading in the age of AI, wherever you get your podcasts.

0:32Unidentified speaker (UNKNOWN): We

0:32Unidentified speaker (speaker_1): said we wanted to cure, prevent, and manage all disease. All disease. I'm really

0:37Unidentified speaker (speaker_0): just all of them.

0:38Unidentified speaker (speaker_1): And what did people say to that?

0:39Unidentified speaker (speaker_0): They were like, that's impossible.

0:41Unidentified speaker (UNKNOWN): That

0:42Unidentified speaker (speaker_1): is mind-blowing. That is what is uh wow. That's the future.

0:46Priscilla Chan: It is. And we're gonna get to live

0:49Unidentified speaker (UNKNOWN): it. I'm

0:53Unidentified speaker (speaker_1): Becky Quick, and I'm walking a path I never thought I would. It's a path that seemed pretty lonely at first. Our daughter Kaylee has a rare genetic disease called SYNGAP 1. She only produces about half of the SYNGAP protein needed for brain development. Oh wait. wet. That means that she has seizures, developmental delays. and intellectual disabilities. And like most other syngapians, she has autism. There is no cure. Kaylee is 10 years old. Early in 2026, we launched CNBC Cures in this podcast, The Path. It began from my own experience, but became so much more. We are building a space for rare disease families to feel heard and understood, for researchers to hide. highlight groundbreaking discoveries, and for patients to share what it's like getting a diagnosis that can change your entire life. One of the best parts has been hearing from all of you, your rare stories. I love reading your comments on this podcast and on social media. Kasha's mom wrote about her daughter, who also has Syngap 1, and she said, This video hits all my feelings.

2:01Another commenter said, please keep doing these. It feels like some light in the darkness. And that's certainly how it feels for me too. Starting this project and meeting so many patients and families looking for answers, for treatments, for ways to build lives with rare disease, I keep coming back to one question: how do we do it better? It's a question our podcast guest today has asked her entire life. For Dr. Priscilla Chan, it started with why? Why did diseases happen in the first place? She's the co-founder of the Massive Philanthropy Chan Zuckerberg Initiative, which she founded with her husband, Facebook founder Mark Zuckerberg. In 2025, they went all in on what they call BioHub. That's a nonprofit committing billions of dollars to a bold mission: curing and preventing all disease. That's right. You heard that. right, all disease. It's a bold initiative, but they are taking some big steps.

2:56Unidentified speaker (speaker_3): When we started, our goal was to help scientists cure or prevent all diseases this century.

3:01Unidentified speaker (UNKNOWN): With

3:02Unidentified speaker (speaker_3): advances in AI, we now believe this may be possible much sooner. So we're going all in on building BioHub as is the first research

3:10Unidentified speaker (UNKNOWN): organization combining frontier AI and frontier biology. We're bringing together leading AI researchers, scientists, massive compute clusters, and the largest human cell data sets to create virtual cells and virtual immune systems to help advance science.

3:24Unidentified speaker (speaker_1): Chan opened the doors of BioHub's headquarters in California, where we sat down for this conversation.

3:31Unidentified speaker (UNKNOWN): Hello, Science CSOL.

3:38Unidentified speaker (speaker_1): Priscilla, thank you so much for taking the time to sit down with us.

3:41Unidentified speaker (UNKNOWN): Thank

3:42Priscilla Chan: you for coming out here.

3:43Unidentified speaker (speaker_1): I know that you are a doctor and a co-CEO. And on your Instagram uh profile, it says a long lady of other things, including a former teacher. Um, I think you also said you are a super nerd or a science nerd, and you're your a mom. Of all of these things that you are, what what do you think of yourself first? and foremost? And I think I know the answer to that.

4:05Unidentified speaker (UNKNOWN): I

4:05Priscilla Chan: it's gotta be mom. So

4:06Unidentified speaker (speaker_1): what's number two?

4:07Priscilla Chan: Okay, okay. Sounds like I mean that's

4:10Unidentified speaker (UNKNOWN): that's

4:11Priscilla Chan: how you identify.

4:11Unidentified speaker (UNKNOWN): Right,

4:12Unidentified speaker (speaker_1): totally. And so what's number two?

4:13Priscilla Chan: Number two.

4:15Unidentified speaker (speaker_3): Um, I think

4:17Priscilla Chan: it's gotta be science nerd,

4:19Unidentified speaker (speaker_3): but in part because

4:22Unidentified speaker (UNKNOWN): I it

4:23Priscilla Chan: touches so many things and aspects of life, it encapsulates. like we're just so optimistic of where we can be going. And also I love knowing how things work.

4:34Unidentified speaker (speaker_1): You've always been that

4:35Unidentified speaker (UNKNOWN): way?

4:36Priscilla Chan: I think so. I've just always wanted to know why. I always knew I wanted to help kids somehow. Take care of kids, educate kids, um, help them feel well, be well. Um, and I always wanted to know how the human body worked. And I think the earliest like core memory where it went from I like this to I need to do this was um when my grandfather passed. Um Uh, my grandfather died when I was in middle school. Uh when I was like around 12 years old. And we came from sort of a family with relatively low medical literacy. And he went from being totally well, dropping me off at school that morning, to my cousins picking me up from school and rushing me to the hospital to say goodbye by the end of the school day. And for years, that's all we knew. That's all I knew and understood. And

5:43we like there were very vague explanations, but no one could tell me why. And when I got a chance in high school to design an independent study, I wanted to know why. Why Why why he he got gets

5:59Unidentified speaker (UNKNOWN): sick

5:59Priscilla Chan: so fast. And so I um knew he had kids. cancer. Um, my school was very supportive. I bought a cancer textbook and I just started reading

6:10Unidentified speaker (UNKNOWN): it.

6:10Priscilla Chan: And that was they gave me course credit, but really I was trying to answer why for myself.

6:17Unidentified speaker (speaker_3): And if you asked me, actually, like this is not

6:20Unidentified speaker (UNKNOWN): my

6:20Priscilla Chan: natural habitat. I love it here now, but this is not my natural habitat. So at the in college. and in med school, if you asked anyone what I the niche that I loved was the healing niche, to stand alongside families, to sit with them and to understand and to support. And that's still incredibly important to me. And sort of like needing to tinker and to know exactly why.

6:51Unidentified speaker (UNKNOWN): I

6:51Priscilla Chan: if we look back, you know, that's why I ordered that cancer textbook in high school. But it didn't become like a need to do a passion until much later.

7:04Unidentified speaker (UNKNOWN): What what happened? What did you find out about your grandfather when you and you did this study prospect?

7:10Priscilla Chan: So I think what happened was that he had a GI bleed because of his cancer. But it wasn't actually his cancer that killed him. It was a GI bleed, and it was just not talked about. Was

7:26Unidentified speaker (UNKNOWN): he getting

7:26Unidentified speaker (speaker_1): treatment?

7:27Priscilla Chan: He was getting treatment.

7:28Unidentified speaker (speaker_1): You just didn't know where.

7:29Priscilla Chan: I knew it's so complicated. There are some cultures where you don't really talk about health issues and you just brush it under the rug and you assume. that, you know, the standard course of treatment is going to be fine. Um, and I and it probably was fine, and this probably was just the course, natural course for him, but it felt so unsettled for me to not know why.

7:58Unidentified speaker (UNKNOWN): Yeah.

7:58Unidentified speaker (speaker_1): You were really close to your grandfather too. Mm-hmm. Your mom and dad, um were immigrants and they were working two jobs a day to make sure that you guys had a roof over your head and you had food. But it was

8:09Unidentified speaker (speaker_3): your grandfather who was and your grandmother who were home taking care of you.

8:13Unidentified speaker (UNKNOWN): I

8:13Priscilla Chan: look I grew up in a multi-generational household in our three bed, one bath. I had my two grandparents, my two sisters, and my two parents. And we just that was how we grew up and we all took care of each other.

8:27Unidentified speaker (speaker_3): Um, did you feel resolved when you finished your project and kind of came to your conclusions about what had happened to him?

8:35Priscilla Chan: I think what I learned was not like I I think I've pieced together what happened to him. But I think oftentimes we just look at the surface level of

8:47Unidentified speaker (UNKNOWN): like,

8:47Priscilla Chan: you know, someone has this symptom, you treat this symptom with this. drug or treatment course or whatever it is. And what it left with me is like, no, I need to know exactly what happened. And I need to know exactly the course of events, and I need to know like the pathophysiology. And if we don't know Kwe why, we can't do better and we can't help uh the next patient. with a better course of treatment. And so I think what it left with me was a very deep needing to know why and being unsatisfied if we don't understand exactly why something is happening. So then you went to Harvard

9:31Unidentified speaker (UNKNOWN): and you went to

9:32Priscilla Chan: medical

9:32Unidentified speaker (UNKNOWN): school and you

9:33Unidentified speaker (speaker_1): wound

9:34Unidentified speaker (speaker_3): up at UCSF for your residency.

9:37Unidentified speaker (UNKNOWN): Why

9:37Unidentified speaker (speaker_3): why UCSF?

9:39Priscilla Chan: For two reasons. I came out I Mark, you know, dropped out of college very famously. I finished many more degrees than him.

9:47Unidentified speaker (UNKNOWN): Um and uh

9:49Unidentified speaker (speaker_3): he was

9:50Unidentified speaker (UNKNOWN): out

9:50Priscilla Chan: in Palo Alto. And I came out to Palo Alto and I took a year off between college and med school to teach. I was like, I'm gonna go to the best med school available to me and hopefully it's close enough where we can continue this relationship. And uh thank goodness UCSF saw something in me because uh my life would look really different if we didn't, I didn't get out into UCSF. It's a very special place. Most people don't know anything about it because it doesn't have an undergraduate Graduate program. Um, it's a medical canvas in the UC system, and it does two. phase. It does cutting as research. It's what we call a tertiary or quinary care center. It treats patients with very rare and exotic diseases, as well as Cotton. And it has a dedication to serving the public and public good. And so it allowed me to both grow, continue to grow my scientific brain, as well as be able to serve.

10:51those who are traditionally not well served by the medical system.

10:54Unidentified speaker (speaker_3): I mean, I know why I got to rare, but I think this is why you got to rare disease, right? What happened? So I trained as a pediatrician

11:01Priscilla Chan: at UCSF. And the kids, really babies and young children that end up at UCSF, CSF oftentimes don't have a diagnosis or they have a series of letters that describes a mutation. As a trainee, as a medical student, as a resident, you're like, I don't know what this is. And when I look it up in the sort of like general textbook, it's not there. So then you're like, Am I the only one who doesn't know? And then you quickly discover that nobody knows. And then a parrot parent gives you a PDF in the patient room. I

11:41Unidentified speaker (UNKNOWN): mean,

11:41Priscilla Chan: this has happened to me so many times, and I can still imagine it happening. And they're like, here it is. This is everything we know about my kid. And you read it and you're like, wait, this doesn't tell me what IV fluids to order, what kind of diet, what medications work. Like, this is barely anything. And this is everything we know.

12:02Unidentified speaker (UNKNOWN): It's

12:02Priscilla Chan: supposed both shocking how thin the knowledge is on these mutations or these diseases, and how much trial and error there has to be. You, I'm sure you've been in this seat where it's like, actually, could you tell

12:21Unidentified speaker (UNKNOWN): me what

12:22Priscilla Chan: will help your kid? I'm happy to do it, but like what has worked. in your experience?

12:28Unidentified speaker (UNKNOWN): And

12:29Priscilla Chan: that's what we're going on with really rare diseases. And that's when I got rehooked into basic science. Because I thought by going to medical school, I was going to know it. I was going to know the answer. So I if I just studied what they told me, I'd be able to help the kids that came in through the door. And that's not true because we don't know enough yet about how the human body works. We do have to go back to the pipettes and the lab at PCR and all those things because we have to push the frontier of knowledge. You know this better than most people. is It's just sometimes you need you just need hope. either for yourself or for the next kid to keep going.

13:21Unidentified speaker (speaker_3): Yeah, I mean, um hope goes a very long way. And I love what you are doing by focusing on the basic building blocks and tools of science to get us back to that. I've got a million questions.

13:36Priscilla Chan: Almost 11 years ago was when

13:38Unidentified speaker (speaker_3): you

13:38Unidentified speaker (UNKNOWN): all

13:39Priscilla Chan: started

13:39Unidentified speaker (speaker_3): the Chan Zuckerberg

13:40Priscilla Chan: Initiative. You

13:41Unidentified speaker (speaker_3): were still finishing up the finishing touches when

13:44Priscilla Chan: what was going

13:45Unidentified speaker (speaker_3): on in your life?

13:46Priscilla Chan: Oh my gosh. My firstborn, Max. We were just writing down our hopes and dreams. And I was like, and it was just it was such a first time parent thing to do. It's like, what are our hopes for this? Little did you know survival was the first hope after having. your first child. Um, but we really took a step back and said, what do we want to contribute? What do we want to do? What do we think we could actually do to make the world a better place for all children, including our own? And what we we knew we were just getting started. We knew very little, but we knew that

14:26Unidentified speaker (UNKNOWN): Mark

14:26Priscilla Chan: had. experience as an engineer. He had experience building things, breaking things down into components, understanding them, and then building out from there. I had the experience of being on the front lines with kids either in the classroom or in the hospital and seeing like where the gaps were. And so that's where we went from. Like, what do we as people bring additionally to the table?

14:51Unidentified speaker (speaker_3): What

14:51Priscilla Chan: are your

14:51Unidentified speaker (speaker_3): superpowers?

14:52Unidentified speaker (UNKNOWN): Yeah.

14:53Unidentified speaker (speaker_3): And how do you deploy them?

14:54Priscilla Chan: How do we deploy them to make a contribution? Because one of the first things we learned is that this work is so much bigger than one person, one organization, one team. It's really, you have to work together with many others in the field of science, in this case, and figure out what you bring uniquely. to lift everyone else up. What what were the early

15:18Unidentified speaker (speaker_3): experiences that kind of taught you that? Getting to that point? Were there some failures along the way where you thought, this is not enough? We have to go bigger, broader?

15:25Priscilla Chan: Well, first you just look at the numbers. You know, uh the we have an incredible scientific engine in our country. And w the amount that we contribute, if you just look at the financials, is like 1%. one percent. So it's not something any one group can do.

15:42Unidentified speaker (UNKNOWN): And

15:42Unidentified speaker (speaker_0): then

15:42Priscilla Chan: what you start

15:43Unidentified speaker (speaker_3): You guys personally at CZI contribute one percent?

15:46Unidentified speaker (speaker_0): I think it's that.

15:48Unidentified speaker (UNKNOWN): Um

15:48Unidentified speaker (speaker_3): getting into this, I mean, you're about to be first-time parents. You have an incredible amount of wealth, and you all made a pretty big decision. And I think you signed on to the giving pledge. You said that you were going to give ninety-nine 99% percent of of your wealth from from Meta in your lifetime that you'd be giving that away. So at that point, I think it was something like $45 billion that we were talking about. As of this week, I think it's closer to $255 billion. Those are big, big, big numbers. How do you figure that out? Like, what do we do with this? How do we do it? Because that's just so exponentially uh I think you can numbers.

16:25Priscilla Chan: There's both the urge. urgency, which we have felt, but we realized in our urgency that we needed to figure out the niche where we could uniquely contribute. In science, we just really hit the flywheel. Like we uh one of our first investments was um in single cell sequencing. All of your cells have the same genome,

16:49Unidentified speaker (UNKNOWN): but

16:49Priscilla Chan: they're obviously very different. Your hair cell is different than your heart cell. They share the same genes, exact same genes. What is it that makes them different? How does how is it that they work so differently? And so you need to start looking at the RNA level. What parts of the genome are they reading and transcribing for their function? And we we just we funded scientists to say, like,

17:12Unidentified speaker (speaker_3): how do you

17:13Priscilla Chan: do this? Let's like let's spread write it. down. And then we just hit the positive flywheel of like, oh yeah, we can look at the lung, we could look at the kidney. During COVID, we discovered a whole new s type of lung cell that is uniquely um uh affected by COVID that no one knew before. We realized that we were looking at different cell types. that no one had ever characterized. And that's how early we are in truly understanding how the human body works. Um, the criticism was this is just stamp collecting. Like there's so much knowledge. You're just generating numbers and letters. And what is the meaning of this?

17:57Unidentified speaker (UNKNOWN): That's

17:57Unidentified speaker (speaker_1): the a practical use for it.

17:58Priscilla Chan: Yeah. But from our perspective, Rick Rego's was like, how can you debug something? How can you find the error when you don't understand the underlying system that the Hubid is built on? And for him, doing that single cell sequencing laid that foundation. For me, I knew that there were kids out there that had like 40 base pairs that were different. And what did those 40 base pairs do that made them? so sick and grow and develop so much more differently than other kids? That's it. 40 letters in their genome. It has to mean something. And so we were willing to go down that path gathering this information. And then we hit an amazing flywheel where people started building together. We funded maybe a third now of what is now the human cell atlas looking at the RNA transcriptome. But because we put it out there as open science, open source, come join us. People started using it and then also realizing, oh, this is useful.

19:08I can contribute to this. So now it's one of the largest RNA repositories of the different cells in your body. And the m vast majority of it isn't funded by us. It's a community that has come together. And that's super powerful. Imagine our delight when large language models came on board. Because the power of large language models is making sense out of a whole lot of information. Too much information for any one human brain. to actually understand. But we had too much information for any one human being to understand that we thought could explain how your your body works. And so we were like, we've got to put these together. When

19:55Unidentified speaker (speaker_3): did that happen? When did that kind of connection with the large language models, everything we're doing right now with CCI and BioHub? Whoa.

20:04Priscilla Chan: Immediately when we people started, you know, I this

20:07Unidentified speaker (speaker_3): is going back years at this point.

20:08Unidentified speaker (UNKNOWN): It's

20:09Priscilla Chan: years ago.

20:09Unidentified speaker (speaker_3): Yeah.

20:10Priscilla Chan: I remember being like, what is an LLM? Right? Because it's not my background. Right. And I'm looking it up and I'm like, oh my God. I still I I actually, this will make you laugh. I really need to know why things work. So I started taking linear algebra. It's all based on linear algebra. And I was like, okay, I took it was not a very sophisticated course, but I took enough to understand. Okay, so we're making sense of patterns. I knew it was going to be big because we had the ability to generate this data and work with the community to build this data. And this tool is Was coming online that was still early, but was doing amazing things. A little bit more than a year ago, we started. talking to the ESM team that was known for building protein monarchs.

20:55Unidentified speaker (speaker_3): Evolutionary scale models. That's what ESM is

20:58Unidentified speaker (UNKNOWN): for

20:58Unidentified speaker (speaker_3): people who don't know it. And it's kind of phenomenal when you put when you pulled that in, scientists were able to compute structures for 1.1 billion proteins in a week.

21:08Priscilla Chan: Yes.

21:09Unidentified speaker (speaker_3): What does that match match up to like say historically? What could be done?

21:13Priscilla Chan: This is kind of a fun story. And I don't think people realize how biology works. You you do. I

21:19Unidentified speaker (UNKNOWN): don't

21:19Unidentified speaker (speaker_3): know. Not

21:19Unidentified speaker (UNKNOWN): like

21:20Unidentified speaker (speaker_3): you do.

21:21Priscilla Chan: For biological breakthroughs, you have to be clever and kind of lucky. Right. And um, some of the most amazing breakthroughs have come from people like being really creative and seeing the connections between things. Um

21:39Unidentified speaker (UNKNOWN): you know

21:39Priscilla Chan: CRISPR came out of work on, I want to say bacteria and yogurt. I don't know if you know this, but GLP1s comes from a guy at the VA who was studying Gila Monster V Venom.

21:54Unidentified speaker (speaker_3): Yeah. And it was a Pfizer who originally had it and put it back on the market afterwards.

21:58Priscilla Chan: Yes.

21:58Unidentified speaker (UNKNOWN): Yeah.

21:59Priscilla Chan: It it went from Gila ghila Monster Venom to diabetes to I I mean, who knows? The it could the ceiling is high. Someone got lucky and studied something random and it was like, oh my gosh, I see the connection. It is not systematic. It is, you can't say, I have this problem, how do I get to an answer? And I think the thing that's so powerful about the rare disease community is that you guys have seen both how frustrating it is. to wait and be like, maybe someone will see a connection that I don't see, or maybe a scientist will get interested in my disease. And you kind of either sit and wait and try to get lucky, or you say, This doesn't work. We need to systematically look at what my kid or these groups of kids have. understand the genetic basis of it, and then keep marching until we understand why and what we could do differently. What I believe the future of medicine is, is we can look at the genetics, say, ah, this set of genes and inputs changes the way that this group of cells work. But if you design a protein that looks like this, then you change the function

23:17of the cells and you can help them op work correctly. That has to be the future of medicine. And the incredible contribution of the rare disease community is that they saw it first. You've seen it first, you've pushed for science that works that way. And a lot of rare disease groups, as you know, are gathering data. patient registries, samples, data sets to allow scientists to build upon this. You think that

23:47Unidentified speaker (speaker_3): the rare disease model is really kind of the gateway to personalized medicine for everybody, to

23:51Unidentified speaker (UNKNOWN): solving

23:52Unidentified speaker (speaker_3): all disease?

23:53Priscilla Chan: Yes. It's for sure. The future of medicine has to work this way. And because right now, let me give you a why. a wild like example. Like very common disease, depression. Like when you're diagnosed with depression, a doctor will start a common drug.

24:15Unidentified speaker (UNKNOWN): And

24:15Priscilla Chan: then you'll wait like six to eight weeks. Did it did it help? It didn't. Oh, I wonder why. Let's try the next drug. But we actually don't know why one drug worked and one drug. didn't. And we actually don't know the genetic basis or the uh sort of changes that happen that lead someone to or

24:34Unidentified speaker (speaker_3): why one drug works for one person and another

24:37Unidentified speaker (UNKNOWN): for

24:37Unidentified speaker (speaker_3): somebody else.

24:38Unidentified speaker (UNKNOWN): But that's

24:40Priscilla Chan: suffering and poor treatment that a a patient has to go through

24:47Unidentified speaker (speaker_0): in

24:48Priscilla Chan: searching for the right treatment for a common disease.

24:51Unidentified speaker (UNKNOWN): But

24:51Priscilla Chan: what if we actually understood sort of the genetic predispositions of someone and say, you're most likely to respond to this treatment? That's great. That's better. Or for someone who has something very bespoke and uh unique to them, we can say, you have this uh set of genes that lead. this protein to be misfolded. And this is where a model like ESM that does protein folding can already do, which is weak design proteins straight from the model, a computational model, to give us instructions, and we can make those proteins in and they fold the way we would. expect and they bind to what we want it to bind. We saw that when the models came out a couple months ago. And like that is like designing treatments for the future.

25:52Unidentified speaker (UNKNOWN): But

25:52Unidentified speaker (speaker_3): it's now.

25:53Priscilla Chan: People are doing

25:55Unidentified speaker (UNKNOWN): it.

25:55Unidentified speaker (speaker_3): Let's talk about how quickly that can happen. Um, and maybe just go back to the origins of CCI CZI again. You're actually in the delivery room when you're working out the final details of this. Explain that. That's really hard for me to imagine. Well, I had an epidural.

26:13Priscilla Chan: So let's start there.

26:15Unidentified speaker (speaker_3): I need an epidural and a bottle of wine to handle

26:17Priscilla Chan: that. But we were working through like, what do we bring to the table? And what do changes do we? want to see? And it was not, it was about organizing our thoughts and making a commitment. Like we are committed to this work. And sort of the path that we're gonna take changes. Like here we are talking about large language models 10 years ago. That was not a thing that we could have written down. But we're committed to doing the work. in learning and growing as we sort of learn more about what's possible. We have learned a lot, and we've also got a ton of new tools. And I think that that's the thing that's so exciting. And we set we originally set out, well, let's walk through the true timeline. We said we wanted to cure, prevent, or manage all disease. All disease.

27:14Unidentified speaker (UNKNOWN): Underline that.

27:15Priscilla Chan: Just all of them.

27:16Unidentified speaker (speaker_3): And what do people say to that?

27:17Unidentified speaker (speaker_0): They were like, that's impossible.

27:20Priscilla Chan: And we well, we thought, okay, why? Well, if you look at the pace of sort of uh uh of scientific discovery, it's accelerated, but not that fast. And we're like, okay. And they were like, well, maybe one. And I was like, no, no, no, no. The point is not one disease. Um, one disease would lead you down the path of saying, let's find those clever connections. It was very important that it was all disease because it was about truly understanding how the human body works so that we could systematically work through it uh a different different way ways that it can go wrong. And so that's all part set us on a very specific strategy of deep understanding of how the body works. And then we talked to scientists who were like, okay, scientists could barely keep uh uh keep a straight face while talking about this. We're like, okay, but by humor humorous, us, why? And they would say, like, we don't have enough interdisciplinary collaboration. We don't have shared tools. We don't have the

28:31data sets. Publishing is not moving as fast as it can be. And we're like, okay, you've just still outlined what we should tackle first. So that's how we got started. And then we kept going, we kept going, and we were like, okay, we're making progress on these things. And now if we said at the a at the end of the century, if I said that to you now, you'd say, why so long? Right. To cure all disease by the end of the century. Yeah. Because now with the tools that we're seeing and the speed at which new knowledge is being learned and the accuracy in which we can speed up the accuracy of our science that's sped up by computation with models and then in the lab. it's fast.

29:16Unidentified speaker (speaker_3): So what what do you consider success? What what would success look like in five, 10, 20 years? What do you think is possible?

29:24Unidentified speaker (speaker_0): I bet

29:25Priscilla Chan: sometime by the end of next year, we're seeing discoveries and uh impact in animals and humans that have been empowered by models that we're building and using today. It used to take decades to get a clinical trial put together. Rare disease groups have broken that mold. We have rare disease groups that we've supported that have gone from not knowing what their mutation meant to designing a gene therapy that's in humans now, within 10 years. The program has existed for 10 years. That's lightning speed. But that's without sort of the foundational models and data sets and research that we have coming online today. And so that can be even faster. And the exciting thing is that there's momentum across the scientific ecosystem of people coming together to. build this.

30:28Unidentified speaker (speaker_3): Let's talk about the origins of BioHub because you started the Chan Zuckerberg Initiative almost 11 years ago. A year later was BioHub. Why why a different organization? Why a different grouping?

30:39Priscilla Chan: The for us, the BioHub really represents a focus on basic science. And now uh frontier science and frontier AI coming together. Um, and it was important that that was a clear position that we took and the and biohook took to say this is what we bring to the table.

31:00Unidentified speaker (speaker_3): And let's talk about what you're next hoping to do. How did you get to a rare as one? How how did that come about? What's the kind of goal of the program? What are you doing right now?

31:11Unidentified speaker (UNKNOWN): So

31:11Priscilla Chan: rare Rarest as one started eight years ago. And I what it wasn't really on my radar because we were working on, like, we're working on petri dishes and cells, single cells. And and I was, we were just gonna build our way up. And Tanya, uh, who runs the program, came to us and said, Well, like actually people moving science fast right now are rare disease groups. And I

31:38Unidentified speaker (UNKNOWN): at first

31:39Priscilla Chan: I was like, I don't know, it's not a traditional area for philanthropy philanthropy to fund. And I was really, uh, it was an unf a new area for me, and I was not familiar with it. But she started showing me that the work that the rare disease groups had done around natural history, registries, samples, um, actually pulling together. patients for signs to move quickly. And I was like, Yeah, I I believe you because I've seen those patients in the hospital. And those patients and families could move mountains. And I was like, okay, that is true. These people are powerful and they have the desire, the motivation to do this. And I was like, okay, let's try it. Let's let's just try it. We did the first cycle and and we were super like cautious about it and sort of thoughtful of uh how this would come together. And we were just completely blown away by the patient groups that uh applied and uh how they were already doing work with so little and were helping each other. already and it was that cohort effect of like how do we do this how do we do this together how how can we teach each other that

32:57was so powerful and like the results are undeniable 10 years eight years in uh groups are you know driving research that didn't exist before driving clinical trials that didn't exist FDA uh approved studies um for treatment treatments for genetic therapies. Like that's lightning speed. And so it's been incredible. And now, I always believe this, but now I see the credible pathway. All of medicine is gonna go this way. And so I can confidently I would definitely say today that I probably couldn't even say three years ago

33:38Unidentified speaker (UNKNOWN): that.

33:38Priscilla Chan: They're not just trailblazing for their own disease or for rare disease groups. They are trailblazers for the future of medicine, which is so exciting. And the legacy that these families are going to leave is going to be huge.

33:53Unidentified speaker (UNKNOWN): Where

33:54Unidentified speaker (speaker_3): do you think you go from here?

33:56Priscilla Chan: I think you start looking at how you can actually start applying their lessons. to how the human body works. And like that's the goal. The goal is, you know, I I for any one group, yes, your mutation is the your top priority and it should be, but they're actually showing us the future of science. And so how can we take those lessons, take that power that the patients and families have had and help apply it to move medicine forward for everyone?

34:33Unidentified speaker (UNKNOWN): It's

34:34Priscilla Chan: really exciting. It really is. It's mind-blowing.

34:37Unidentified speaker (speaker_3): Yeah. I am so hopeful sitting here talking to you about this. And it's, you know, you go through your ups and downs where you think you're making advances, think maybe you're not. But when you sit down and expose a bigger picture, I mean, that is my that is. mind blowing. That is what it is. Um, wow, that's the future.

34:55Priscilla Chan: It is. And we're gonna get to live it. I think it's all gonna move faster. And I think the thing that's interesting is that the rare disease groups are not just pioneers for themselves. I think we're gonna look back and realize that the rare disease groups were pioneers for all of biomedicine.

35:13Unidentified speaker (UNKNOWN): And

35:13Priscilla Chan: we're gonna see the way. that research goes from research to clinical trials to treatments much faster because we've seen groups pioneer it happen differently with the rare disease groups and with the foundational bottles that are getting built today.

35:35Unidentified speaker (speaker_3): From your lips.

35:37Priscilla Chan: I

35:37Unidentified speaker (speaker_3): mean, that is the promise. all of us are hoping for. Yeah.

35:40Priscilla Chan: You're a

35:41Unidentified speaker (speaker_3): scientist and a tinkerer and somebody who looks at how things work, which has you really grounded in reality. But I I think you have to be a dreamer to think about the things that you're doing too. How how do you see yourself? How do you and Mark kind of play together in in a relationship on being grounded in science and in engineering? but then also dreaming big dreams for this stuff.

36:08Priscilla Chan: I think for us, as the realization is we don't have to know the whole path there. We can set a goal. We want to cure, prevent, and manage all disease. And then we just need to do the next thing.

36:23Unidentified speaker (UNKNOWN): And

36:23Priscilla Chan: if we try the next thing and we learn from it, it's the speed of learning that's going to get us to the goal. It's not that we know exactly the right path and all the steps to get there. It's a willingness to do something that we don't know whether or not it's going to work and learn from it and keep going and get smarter.

36:43Unidentified speaker (UNKNOWN): And

36:43Priscilla Chan: I think that's what we've done over the past 10 years. And um what's really fun is that. you know, Mark from his perspective is just like, of course, it takes a long time to build things. I've built things, takes a long time. And you need to build the foundation and you need to sort of build the learning engine. And once you have that going, you it you're gonna make progress. And for me, I'm always like a hawk looking at like, is this gonna matter for patients? Like, are we doing this? because we're just truly curious people? Which is fine, but for me, I'm truly curious because I want human lives to be better. Um, and so we're always bringing those perspectives and sort of continuing to hone the learning engine that is biohub. And um, and that's allowed us to build pretty great things with great people.

37:37Unidentified speaker (UNKNOWN): That

37:37Unidentified speaker (speaker_3): sounds like you carry some. pretty heavy responsibilities. Do you ever get tired? You know, I will say that yes,

37:46Priscilla Chan: of course.

37:47Unidentified speaker (speaker_3): But there have I not

37:49Priscilla Chan: sure there's been a more exciting time in in science and in medicine. And so I my mind is blown, and I'm delighted by the work that we get to be able to

38:01Unidentified speaker (UNKNOWN): do. What kind

38:02Unidentified speaker (speaker_3): of reaction? do you get when you tell people today that you want to cure all disease? Uh I people are like, yeah, of course that's going to happen. And um and they ask me how, instead of saying

38:17Unidentified speaker (UNKNOWN): that's

38:17Unidentified speaker (speaker_3): not

38:18Unidentified speaker (UNKNOWN): possible.

38:18Unidentified speaker (speaker_3): I think back to your time at UCSF and I I just wonder, I know you said there are a lot of families that the patients, the families stuck with you. Is there one in particular who really jolted you? Maybe one of your

38:32Unidentified speaker (UNKNOWN): first

38:32Unidentified speaker (speaker_3): patients saying that along the

38:33Unidentified speaker (UNKNOWN): way? Oh

38:35Unidentified speaker (speaker_3): boy.

38:36Unidentified speaker (UNKNOWN): There

38:37Priscilla Chan: are two that come to mind when you ask that question.

38:40Unidentified speaker (speaker_3): We had a kid who had

38:42Priscilla Chan: cystic, we had lots of kids with cystic fibrosis, actually.

38:46Unidentified speaker (speaker_3): But he was like the picture of health.

38:49Unidentified speaker (UNKNOWN): I

38:49Unidentified speaker (speaker_3): was like, what? why? You look so good. You were, you were, he was a college-age kid

38:54Unidentified speaker (UNKNOWN): and

38:54Unidentified speaker (speaker_3): he was doing college age things.

38:57Unidentified speaker (UNKNOWN): And

38:57Unidentified speaker (speaker_3): I'm like, why is this kid

38:59Priscilla Chan: doing so well when I see so many kids with other kids with cystic fibrosis that are really struggling? What is the difference? What happened here? And so sometimes the positive outliers make you say, maybe there's something there, like maybe there's something that we're not seeing that helped this kid thrive. And then there was another case that I I think as a doctor you always remember. Um the first patients that you sort of take care of uh until the end of their life. And I took care of this kid for eight weeks every day. in the hospital. And sh um, and it was a relapse. It was a it was a cancer, pediatric cancer that had relapsed. And she had done so well, and she had gone home and she'd lived her life. And she was a teeth too, and she came back. And uh the medicines didn't work anymore.

39:58Unidentified speaker (UNKNOWN): And

39:58Priscilla Chan: then you have to ask yourself, like, why? Why didn't did the medicines work? And honestly, I think uh you just never forget the patients that you say goodbye

40:10Unidentified speaker (UNKNOWN): to. But

40:13Unidentified speaker (speaker_3): you honor their memory with what you're doing today.

40:15Unidentified speaker (UNKNOWN): Yeah. You

40:16Priscilla Chan: know, she wrote me a card, I still have

40:18Unidentified speaker (UNKNOWN): it. These

40:21Priscilla Chan: are the things you save.

40:23Unidentified speaker (speaker_3): Yeah. As a

40:24Priscilla Chan: parent

40:24Unidentified speaker (speaker_3): of a child with a rare disease, I'm grateful. Thank you for what you all are doing.

40:29Priscilla Chan: We're all doing our best. You're doing incredible work. I don't think people realize how much you do in all your different hats.

40:36Unidentified speaker (speaker_3): No, it's it's not that. It's you're finding solutions. I can't do what you guys do. I've been blown away. So thank you.

40:45Unidentified speaker (speaker_1): I'm so grateful that you've joined me for another step on the path. We are keeping this journey going. Next time on the path, we talked to a mother and scientist, Alison Barrent. Alison had to make an impossible choice to make her daughter's life better. We'll tell you all about it.

41:02Unidentified speaker (speaker_3): What does neuroplasticity look like in a kid with a neurodevelopmental disorder? And what does it look like for us as adults? And what I really put my hat on was I can learn Spanish at age 35. I may have an accent, but I can speak it fluently. So if I can learn at age 35 a brand new language, why can't my daughter learn at age five? Why can't she learn at age 10? She might have an accent, but you know what? If she can speak, if she can live independently, if she can be potty trained, if she can make a friend, that is a different life. than what I'm reading on Wikipedia right now.

41:41Unidentified speaker (speaker_1): You can watch or listen to the path on YouTube, Apple Podcasts, CMBC.com, Podcast Platforms, or by scanning the QR code on the screen. We've got some exciting episodes dropping soon with leaders in the rare disease space, so make sure you're subscribed and that let you tune in. Thank you to the team at CNBC, CMBC, and thanks to all of you. We'll see you next time.

42:20Unidentified speaker (speaker_0): And the women I talk to aren't waiting for the future, they're shaping it. I'm Julia Borstin, Borston, Senior Media and Tech Course. Correspondent at CNBC. This is CNBC Changemakers, where I talk with the female leaders transforming business as AI reshapes the world. Follow and listen to CNBC Changemakers, women leading in the age of AI, wherever you get your podcasts.

This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights